Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
salbutamol sulfate
Aspen Pharma Pty Ltd
salbutamol sulfate
Registered
BUTAMOL- Consumer Medicine Information Page 1 of 3 Butamol _SALBUTAMOL _ CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Butamol 2.5 and Butamol 5. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risk of you taking this medicine against the benefits it is expected to have for you. ASK YOUR DOCTOR OR PHARMACIST IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE. This medicine is only part of a general plan to help you manage your asthma, or other chest conditions. You should discuss this plan with your doctor. ASK YOUR DOCTOR TO CHECK YOUR TREATMENT PLAN REGULARLY. KEEP THIS LEAFLET WITH THE MEDICINE. You may want to read it again WHAT BUTAMOL IS USED FOR The name of your medicine is Butamol 2.5 or Butamol 5. The medicine is delivered through a device called a nebuliser. Butamol contains a medicine called Salbutamol, which belongs to a group of medicines called beta-2- agonists. These work rapidly to open up the air passages in your lungs. Salbutamol is inhaled into the lungs for the treatment of Asthma. Asthma is a disease where the lining of the lungs become inflamed (red and swollen), making it difficult to breathe. This may be due to an allergy to house dust mites, smoke, air-borne pollution and other irritants. Salbutamol opens up the air passages in people suffering from asthma, bronchitis and other breathing problems. It may also be used before exercise to keep your air passages open if you start to wheeze or have difficulty breathing each time you exert yourself. Salbutamol inhalation may be used for the management of other conditions that are not mentioned above. Your doctor will be able to tell you about the specific condition for which you have been prescribed Butamol 2.5 or Butamol 5. This medicine is only available with a doctor’s prescription BEFORE YOU USE IT _WHEN YOU MUST NOT USE IT _ DO NOT USE BUT Read the complete document
BUTAMOL- Product Information Page 1 of 7 BUTAMOL PRODUCT INFORMATION NAME OF THE MEDICINE _ _ _BUTAMOL 2.5, BUTAMOL 5 _ Active: Salbutamol sulfate. (C 13 H 21 NO 3 ) 2 ,H 2 SO 4 Molecular weight: 576.7 Cas No.: 51022-70-9 DESCRIPTION Chemical name: di[(RS)-2-(1,1-dimethyl)ethylamino-1- [4-hydroxy-3 - (hydroxymethyl)phenyl]ethanol] sulfate. Salbutamol sulfate is a white or almost white odourless, crystalline powder with a slightly bitter taste. It is freely soluble in water, practically insoluble or very slightly soluble in ethanol (96 per cent) and in methylene chloride. Salbutamol sulfate 1.2 mg is approximately equivalent to salbutamol 1 mg. Butamol 2.5 and Butamol 5 ampoules are clear, aqueous isotonic, preservative-free nebuliser solutions for single use. BUTAMOL 2.5: Each single dose ampoule contains salbutamol (as sulfate) 2.5 mg in 2.5 mL. Excipients: Sodium Chloride, Sulfuric acid and Water for Injections. BUTAMOL 5: Each single dose ampoule contains salbutamol (as sulfate) 5 mg in 2.5 mL. Excipients: Sodium Chloride, Sulfuric acid and Water for Injections. PHARMACOLOGY _Action:_ beta 2-adrenoreceptor agonist. Salbutamol is a long acting, relatively selective beta2-receptor stimulant. Administration by inhalation results in direct stimulation of beta 2-receptors in bronchial smooth muscle and, hence, bronchodilatation. This is thought to be due to stimulation of adenyl cyclase by salbutamol, resulting in increased levels of cyclic adenosine monophosphate (AMP) within cells. These are thought to inhibit the entry of calcium ions into the cells, thus inhibiting smooth muscle contraction. High levels BUTAMOL- Product Information Page 2 of 7 of cyclic AMP in mast cells may also inhibit the release of histamine and slow reacting substance-A (SRS-A). After administration of salbutamol, stimulation of both beta1 and beta2-receptors occurs because beta2 selectivity is not absolute. This results in the beta1 effect of cardiac stimulation, though not so much as with isoprenaline, and beta2 effects of peripheral vas Read the complete document